Project Grant R21AI201981
Award Date 7/23/26
Completion Date 6/30/28
Dollars Obligated $233K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Baltimore, MD 21205, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded The Johns Hopkins University $703,040 on August 27, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop innovative treatment regimens for Mycobacterium avium complex pulmonary disease. The research addresses a critical gap in MAC lung disease treatment, where current therapies achieve only a 31 percent three-year microbiological cure rate and only one FDA-approved drug exists. The project...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded The Johns Hopkins University a Project Grant of $155,227 under the Allergy and Infectious Diseases Research program (CFDA 93.855) effective June 9, 2025, with completion scheduled for May 31, 2027. The grant supports proof-of-concept research on an unconventional treatment regimen for Mycobacterium abscessus (MAB) chronic lung disease, a rapidly progressive non-tuberculous...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded The Johns Hopkins University a Project Grant of $426,938 under the Allergy and Infectious Diseases Research program (CFDA 93.855) on June 23, 2025, with a completion date of May 31, 2027. The award supports the development of a simplified, cost-effective mouse model of chronic Mycobacterium abscessus lung disease using BALB/c mice that requires only weekly cyclophosphamide administration. This...
- The National Institute of Allergy and Infectious Diseases awarded The Johns Hopkins University $427,521 under Project Grant R21AI190702 on May 7, 2026, to identify genetic markers of beta-lactam resistance in Mycobacterium abscessus. The research aims to determine which genes and mutations enable M. abscessus to develop resistance to imipenem and cefoxitin, the primary antibiotics used to treat chronic lung disease caused by this rapidly growing non-tuberculous mycobacterium. M. abscessus...
- The National Institute of Allergy and Infectious Diseases awarded The Johns Hopkins University $195,640 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research integrating genomic and clinical approaches to define and prevent cefiderocol resistance in carbapenem-resistant organisms. The research addresses gaps in understanding cefiderocol resistance mechanisms and clinical use in carbapenem-resistant organisms, which cause severe...
- The National Institute of Allergy and Infectious Diseases awarded Oregon Health & Science University $442,758 on February 9, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to identify drug targets in Mycobacterium abscessus through fluorescent probe application. Performance runs through January 31, 2028, in Portland, Oregon. M. abscessus causes the most difficult-to-treat and highest-mortality non-tuberculous mycobacterial pulmonary infections in the United...
- The National Institute of Allergy and Infectious Diseases awarded The Johns Hopkins University $149,190 on January 23, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support Project Grant F31AI191794, a doctoral fellowship examining mechanisms of antibiotic persistence in a mouse model of systemic infection. The research develops and uses a mouse model of systemic bacterial infection to study how phenotypically distinct bacterial subpopulations survive...
- The National Institute of Allergy and Infectious Diseases awarded The Johns Hopkins University $225,628 on August 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to identify genetic mechanisms of polyene resistance in Candida glabrata using saturating transposon mutagenesis coupled with next-generation DNA sequencing (TN-SEQ). The project will implement TN-SEQ to mutate and barcode every gene in C. glabrata and profile resistance to three approved...
- The National Institute of Allergy and Infectious Diseases awarded The Johns Hopkins University $233,125 on May 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop and validate a toolkit for studying 1-deoxy-D-xylulose 5-phosphate synthase (DXPS) as a driver of metabolic adaptation in bacterial pathogens. The research targets bacterial central metabolism as a route to novel antibacterial strategies, focusing on how pathogens remodel their metabolism to...
- The National Institute of Allergy and Infectious Diseases awarded $234,000 to the University of Maryland, College Park on May 26, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support research into phagosomal membrane repair pathways during Mycobacterium tuberculosis infection using high-throughput single-cell and single-phagosome analysis. The research deciphers how host cell machinery repairs damage to the mycobacterium-containing vacuole, a process critical...